Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 20.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,036 shares of the company’s stock after buying an additional 508 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Medpace were worth $1,250,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of MEDP. Janney Montgomery Scott LLC boosted its position in shares of Medpace by 40.9% during the fourth quarter. Janney Montgomery Scott LLC now owns 7,098 shares of the company’s stock worth $2,175,000 after buying an additional 2,061 shares during the period. Norges Bank purchased a new position in Medpace during the 4th quarter valued at about $59,163,000. PNC Financial Services Group Inc. boosted its holdings in Medpace by 5.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,750 shares of the company’s stock valued at $2,682,000 after acquiring an additional 488 shares during the period. Coldstream Capital Management Inc. grew its position in Medpace by 5.0% in the 4th quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock valued at $292,000 after acquiring an additional 45 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in Medpace during the fourth quarter worth about $191,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $365.70 on Monday. Medpace Holdings, Inc. has a 1 year low of $227.21 and a 1 year high of $459.77. The stock has a market cap of $11.33 billion, a P/E ratio of 37.28, a P/E/G ratio of 1.74 and a beta of 1.35. The stock has a 50-day simple moving average of $378.15 and a 200-day simple moving average of $391.82.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The firm had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same period in the prior year, the company posted $1.93 earnings per share. The firm’s quarterly revenue was up 14.6% compared to the same quarter last year. On average, equities research analysts predict that Medpace Holdings, Inc. will post 11.66 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of research reports. TD Cowen dropped their price objective on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. William Blair restated an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft reduced their price objective on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research note on Wednesday, July 24th. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a research note on Wednesday, September 18th. Finally, Robert W. Baird cut their price target on Medpace from $430.00 to $413.00 and set an “outperform” rating on the stock in a report on Friday. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Moderate Buy” and an average target price of $420.88.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.